Integral Health Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Integral Health Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-220,000	Closed	-$6.07M	–	92
2023 Q3	$6.07M	Buy	220,000 +145,000	+193%	+$4.41M	0.84%	45
2023 Q2	$2.25M	Sell	75,000 -50,000	-40%	-$1.75M	0.28%	67
2023 Q1	$4.53M	Buy	125,000 +85,000	+213%	+$3.27M	0.91%	43
2022 Q4	$1.43M	Buy	+40,000	New	+$1.39M	0.3%	59

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Integral Health Asset Management's SUPN Position: Q4 2023 in Review

Integral Health Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2023, closing a stake of 220,000 shares — an estimated $6.07M sold.

Integral Health Asset Management first reported a position in SUPN in Q4 2022 and held it in 4 quarters. The position peaked at $6.07M in Q3 2023. 246 funds tracked by Wall St. Rank hold SUPN as of Q4 2023.

Integral Health Asset Management reported no remaining Supernus Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Integral Health Asset Management sold 220,000 Supernus Pharmaceuticals shares in Q4 2023, an estimated $6.07M.
Integral Health Asset Management first reported a position in Supernus Pharmaceuticals in Q4 2022 and held it in 4 quarters.
Integral Health Asset Management's Supernus Pharmaceuticals position peaked at $6.07M in Q3 2023.
246 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2023.

Based on Integral Health Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.